NASDAQ:FRLN - Freeline Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 101.29 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$12.42
▲ +0.28 (2.31%)
1 month | 3 months | 12 months
Get New Freeline Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FRLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FRLN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$25.00
▲ +101.29% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Freeline Therapeutics in the last 3 months. The average price target is $25.00, with a high forecast of $28.00 and a low forecast of $21.00. The average price target represents a 101.29% upside from the last price of $12.42.
Buy
The current consensus among 7 polled investment analysts is to buy stock in Freeline Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021Morgan StanleyLower Price TargetOverweight$28.00 ➝ $22.00High
i
4/6/2021Morgan StanleyLower Price TargetOverweight$28.00 ➝ $22.00High
i
3/29/2021MizuhoInitiated CoverageBuy$27.00N/A
i
3/22/2021MizuhoInitiated CoverageBuy$27.00High
i
3/8/2021Stifel NicolausInitiated CoverageBuy$21.00N/A
i
3/1/2021Stifel NicolausInitiated CoverageBuy$21.00Medium
i
11/25/2020Redburn PartnersInitiated CoverageNeutralLow
i
9/1/2020Evercore ISIInitiated CoverageOutperformHigh
i
9/1/2020WedbushInitiated CoverageOutperform$28.00 ➝ $28.00High
i
Rating by D. Nierengarten at Wedbush
9/1/2020JPMorgan Chase & Co.Initiated CoverageOverweight$27.00High
i
9/1/2020Morgan StanleyInitiated CoverageOverweight$28.00N/A
i
(Data available from 4/19/2016 forward)
Freeline Therapeutics logo
Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Read More

Today's Range

Now: $12.42
$12.10
$12.71

50 Day Range

MA: $13.71
$12.05
$15.25

52 Week Range

Now: $12.42
$11.85
$21.69

Volume

3,900 shs

Average Volume

8,622 shs

Market Capitalization

$445.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Freeline Therapeutics?

The following Wall Street research analysts have issued reports on Freeline Therapeutics in the last twelve months: Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Redburn Partners, Stifel Nicolaus, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for FRLN.

What is the current price target for Freeline Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Freeline Therapeutics in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 101.3%. Wedbush has the highest price target set, predicting FRLN will reach $28.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $21.00 for Freeline Therapeutics in the next year.
View the latest price targets for FRLN.

What is the current consensus analyst rating for Freeline Therapeutics?

Freeline Therapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FRLN will outperform the market and that investors should add to their positions of Freeline Therapeutics.
View the latest ratings for FRLN.

What other companies compete with Freeline Therapeutics?

How do I contact Freeline Therapeutics' investor relations team?

Freeline Therapeutics' physical mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The company's listed phone number is 44-14-3890-6870 and its investor relations email address is [email protected] The official website for Freeline Therapeutics is www.freeline.life.